Loading
TQB6411 is an experimental antibody-drug conjugate from Chia Tai Tianqing Pharmaceutical in phase 2 trials for non-small-cell lung cancer and oesophageal cancer, aimed at EGFR and MET.
TQB6411 is an antibody-drug conjugate developed by Chia Tai Tianqing Pharmaceutical. Its targets are EGFR and MET. ClinicalTrials.gov describes the intervention as: TQB6411 for Injection is administered every 21 days as a treatment cycle. TQB6411 for injection is administered every 28 days as a treatment cycle. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in non-small-cell lung cancer and oesophageal cancer. The largest, NCT07367529, plans to enrol 465 participants with primary completion expected 2028-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.TQB6411's antibody arm binds EGFR on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TQB6411" OR ABSTRACT:"TQB6411") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TQB6411, not a curated reading list.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), MET, EGFR and the tag pipeline.
Shares MET, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares MET, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares MET, Non-small-cell lung cancer and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), MET and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.